ArQule Inc. (Nasdaq: ARQL) reported disappointing results from a Phase 3 study of tivantinib in hepatocellular carcinoma sending the stock price down 27 cents to close at $1.20.
Disappointing study results for ArQule
February 17, 2017 at 16:55 PM EST
